News | July 22, 2023
Glenmark Life Sciences reports robust 25% EBITDA growth in Q1FY24
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
The net profit in the June quarter was also lower than Rs 146.3 crore reported in the March quarter.
Planned investment of approximately USD 90 million to build a state-of-the-art Sandoz Biosimilar Technical Development Center in Ljubljana, Slovenia by 2026
Chlorpromazine Hydrochloride Tablets USP had an estimated annual sale of USD 45 million in the U.S.
Dolutegravir Tablets for Oral Suspension (RLD Tivicay PD®) had estimated annual sales of USD 1 million in the U.S. (IQVIA MAT March 2023)
With this, the number of marketing approvals for its oncology products across 75 countries has gone up to 503
Cyanocobalamin Nasal Spray (RLD Nascobal) had estimated annual sales of USD 69 million in the U.S. (IQVIA MAT Mar 2023)
The company expects to capture a 10 per cent share in Spain’s $6.34 million meropenem market and consolidate its position in other European countries
This product will be manufactured at Lupin's Pithampur facility in India
Sajjan India Limited is looking for expansion, both organically and through acquisitions, to achieve the planned growth
Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic
Subscribe To Our Newsletter & Stay Updated
